Skip to content

Use of new technology for rapid detection of SARS-CoV2

Use of Novel In-vitro Diagnostic Technologies [NAOR platform, Terasystem Breath Analyzer, VIRIONâ?¢ test and Voice Pattern test] and RT-PCR for rapid testing of SARS-CoV2 in Indian Population - Open Skies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/07/026843
Enrollment
10000
Registered
2020-07-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Defence Research and Development Organisation DRDO
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Asymptomatic or Symptomatic Male or Females with 18 years or more of age who are willing to provide informed consent or participation in this research and - who are approaching the research centre with or without suspected COVID 19 symptoms OR - who have been tested or intend to get tested for SARS COV 2 infection OR - patients with diagnosed COVID 19 infection OR - are healthy volunteers

Exclusion criteria

Exclusion criteria: 1. Participants who are unable to voluntarily consent for themselves or have a psychiatric history or dementia or mental retardation etc that impair judgement for participation 2. Inability to undergo the research tests or methods including handling of smart phone applications 3. Inability to submit to answer the required information on the CRF for social or psychological reasons 4. Person under guardianship or protection of vulnerable adults 5. Person deprived of liberty by a judicial or administrative decision

Design outcomes

Primary

MeasureTime frame
To assess the feasibility of use of the novel in vitro diagnostic technologies for testing of SARS CoV2 in Indian Population Test outcomes positive or negative for COVID 19 under each IVD technologies used in the studyTimepoint: 10 days, for the entire duration

Secondary

MeasureTime frame
To assess the novel in vitro diagnostic technologies for diagnostic technologies for rapid testing less than 30 minutes of SARS CoV2 in Indian Population Sample processing timelines from sample collection start of analysis to results Timepoint: 10 days, for the entire duration

Countries

India

Contacts

Public ContactDr Reena Mariya

Defence Institute of Physiology and Allied Sciences (DIPAS)

reena@inmas.drdo.in9868912245

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026